<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92316">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784354</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00062868</org_study_id>
    <nct_id>NCT01784354</nct_id>
  </id_info>
  <brief_title>Acupressure for the Treatment of Raynaud's Phenomenon</brief_title>
  <official_title>Acupressure in Raynaud's Phenomenon- A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: University of Michigan Institution Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of acupressure will be compared to targeted Raynaud's education and will evaluate
      the` frequency, duration and pain of Raynaud's attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a Raynaud's condition score, severity of tingling, numbness and pain of attacks, the
      number of attacks and patient and physician visual analog scale we will assess the effect of
      acupressure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease in number of Raynaud's attacks</measure>
    <time_frame>1-2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Primary Raynaud's Phenomeon</condition>
  <arm_group>
    <arm_group_label>Education</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>target education toward Raynaud's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acupressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acupressure- dilatation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acupressure relaxation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acupressure relaxation protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupressure</intervention_name>
    <arm_group_label>Acupressure relaxation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupressure dilatation</intervention_name>
    <arm_group_label>Acupressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>education</intervention_name>
    <arm_group_label>Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  Have Raynauds phenomenon, with at least 4 attacks in the last week

          -  on stable medications

          -  Willing to attend study visits

        Exclusion Criteria:

          -  smoker

          -  have a history of stroke, heart attack or irregular heart rhythm

          -  uncontrolled blood pressure

          -  physical or mental illness that would interfere with participating in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 10, 2013</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Heather Gladue, DO</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
